A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1
420
about 6.8 years
18+
44 sites in AZ, CA, CO +21
About this study
This trial is testing a treatment called ziftomenib when combined with other medications to treat acute myeloid leukemia (AML). The goal is to see if the treatment is safe and well-tolerated.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Azacitidine
- 2.Take Cytarabine
- 3.Take Daunorubicin
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
azacitidine, cytarabine, daunorubicin, quizartinib, venetoclax
injection, subcutaneous, injection (Injection), oral (Oral Tablet), oral, oral (Oral Capsule)
Primary: Complete remission (CR) rate, Descriptive statistics of adverse events
Secondary: Cmax, Cmax of quizartinib, Cmax of venetoclax, EFS, Median DOR, Median EFS, Median OS, Tmax
Oncology